Equities research analysts expect PetIQ Inc (NASDAQ:PETQ) to report $0.39 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for PetIQ’s earnings, with estimates ranging from $0.35 to $0.44. The firm is expected to announce its next earnings report on Tuesday, August 21st.
According to Zacks, analysts expect that PetIQ will report full year earnings of $0.81 per share for the current fiscal year, with EPS estimates ranging from $0.75 to $0.89. For the next financial year, analysts anticipate that the firm will report earnings of $1.01 per share, with EPS estimates ranging from $0.91 to $1.17. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover PetIQ.
PetIQ (NASDAQ:PETQ) last announced its quarterly earnings results on Tuesday, May 15th. The company reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.04. The company had revenue of $115.10 million for the quarter, compared to analyst estimates of $108.54 million. PetIQ had a net margin of 0.17% and a return on equity of 11.39%. The company’s revenue for the quarter was up 71.8% on a year-over-year basis.
PETQ has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of PetIQ from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Friday, March 16th. BidaskClub upgraded shares of PetIQ from a “hold” rating to a “buy” rating in a report on Wednesday, March 21st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $31.00 price target on shares of PetIQ in a report on Wednesday, April 11th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $28.33.
Shares of PetIQ traded up $0.69, reaching $27.34, during mid-day trading on Friday, according to Marketbeat.com. The company had a trading volume of 276,282 shares, compared to its average volume of 356,659. The firm has a market cap of $653.80 million and a PE ratio of 69.49. PetIQ has a fifty-two week low of $17.03 and a fifty-two week high of $28.70. The company has a quick ratio of 1.09, a current ratio of 2.35 and a debt-to-equity ratio of 0.69.
In related news, CEO Mccord Christensen sold 40,000 shares of PetIQ stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $26.31, for a total transaction of $1,052,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronald Kennedy bought 20,200 shares of PetIQ stock in a transaction that occurred on Monday, May 21st. The shares were acquired at an average price of $17.88 per share, for a total transaction of $361,176.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 76,500 shares of company stock worth $1,925,128. 45.26% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. Fred Alger Management Inc. lifted its holdings in shares of PetIQ by 544.6% during the 4th quarter. Fred Alger Management Inc. now owns 112,302 shares of the company’s stock valued at $2,453,000 after acquiring an additional 94,880 shares in the last quarter. Park West Asset Management LLC acquired a new position in shares of PetIQ during the 4th quarter valued at $19,527,000. Brown Advisory Inc. acquired a new position in shares of PetIQ during the 4th quarter valued at $324,000. Fiera Capital Corp acquired a new position in shares of PetIQ during the 1st quarter valued at $6,651,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of PetIQ during the 4th quarter valued at $3,027,000. Institutional investors and hedge funds own 63.96% of the company’s stock.
PetIQ Company Profile
PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
Get a free copy of the Zacks research report on PetIQ (PETQ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.